Matson downgraded at Wolfe Research, expecting demand risk from China tariffs and lower ocean rates after shares outperformed this year.

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...

Wolfe Research upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) to a strong-buy rating in a report ...

Fintel reports that on November 18, 2024, Wolfe Research downgraded their outlook for Matson (NYSE:MATX) from Outperform to ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of BioMarin Pharmaceutical (NasdaqGS:BMRN) with a ...

Wolfe Research initiated coverage of Veracyte (VCYT) with an Outperform rating and $50 price target Published first on TheFly – the ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.09% of ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Moderna (MRNA) with an Underperform rating and $40 price target Moderna may ...

Food-industry giant McDonald’s is partnering with protein producer Lopez Foods and global agricultural innovator Syngenta ...

Voters really don't like inflation. In fact, whenever there's a sustained jump in the cost of living, the party in power ...

Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...

Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...